MedTrace Logo

Evaluating the Effects of Inarigivir on Immune Response and Viral Markers in Chronic Hepatitis B Patients

NCT03932513 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2020-04-29

No results posted yet for this study

Summary

A single center, open-label, study to evaluate the intra-hepatic effect of inarigivir dose per day and three times per week on immune response and viral markers in virally suppressed patients with chronic hepatitis B infection

Conditions

Interventions

DRUG

inarigivir soproxil

Inarigivir 200mg and 400mg oral tablets, once daily

Sponsors & Collaborators

  • CSI Medical Research Pte Ltd

    collaborator UNKNOWN

  • F-star Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Prof. Lim Seng Gee · National University Hospital, Singapore

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-11
Primary Completion
2019-12-21
Completion
2019-12-21

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03932513 on ClinicalTrials.gov